Diabetes melutus associated with pentamidine isethionate in diffuse cutaneous leishmaniasis

• Autor(a) principal: Costa,Jackson Mauricio Lopes
• Data de Publicação: 1995
• Outros Autores: Moraes,Marta Solange C., Saldanha,Ana Cristina R., Barral,Aldina, Burattini,Marcelo N.
• Tipo de documento: Relatório
• Idioma: eng
• Título da fonte: Revista da Sociedade Brasileira de Medicina Tropical
• Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0037-86821995000400015
• topic: Diffuse cutaneous leishmaniasis; Pentamidine isethionate; Diabetes mellitus; Maranhão State

The authors report a case of a male patient from Bacabal, MA with diffuse cutaneous leishmaniasis (DCL), for at least nine years, with 168 lesions on his body. These were tumour-like nodules with some ulceratmi. He usedpentavalent antimonial (glucantime®) and an association of gamma interferon plus glucantime with improvement of the lesions but relapsed later. Recently, pentamidine isethionate (pentacarinat®) was given a dosage of 4mg/kg/weight/day on alternate days for 20 applications. After 3 months a similar course of 10 application was given 2 times. Later he developed diabetic signs with weight loss of 10kg, polydypsia, polyuria and xerostomia. The lower limbs lesions showed signs of activity. Blood glucose levels normalised and remain like this at moment. Attention is drawn to the fact that pentamidine isethionate should be used as a therapy option with care, obeyng rigorous laboratory controls including a glucose tolerance test.